CTLA4 and melanoma: The GSE91061 cohort documented the effects of anti‐PD‐1 and anti‐CTLA4 immunotherapy in patients with melanoma and non‐small cell lung cancer, while GSE93157 studied the responses of melanoma and lung cancer patients to anti‐PD‐1 treatment.